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Letter to the EditorReactivation of hepatitis B virus after transarterial
chemo-embolization for hepatocellular carcinoma in one patient
with negative hepatitis B surface antigenTo the Editor:
We read with interest the excellent paper by Sanchez et al., dem-
onstrating successful entecavir treatment of a patient who devel-
oped severe reactivation of hepatitis B virus (HBV) due to potent
chemotherapy containing rituximab [1]. The reactivation of HBV
following treatment with chemotherapy is well recognized and
the incidence can be substantially decreased by pre-emptive
anti-viral therapy [2]. It occurs in two clinical settings: (1) in
chronic carriers with positive hepatitis B surface antigen (HBsAg)
and (2) in those with prior HBV infection who are HBsAg-nega-
tive and have antibodies against hepatitis B core antigen (anti-
HBc) [3,4]. For HBsAg-positive patients with hepatocellular carci-
noma (HCC), transarterial chemo-embolization (TACE) can also
lead to the reactivation of HBV replication [5]. Nevertheless,
whether TACE causes severe reactivation of the virus for patients
with resolved HBV infection is still unknown. Herein, we report a
case with negative HBsAg presenting with reactivation of HBV
after the application of TACE for HCC (see Fig. 1).
This 78-year-old male patient had a history of HBV infection
for more than three decades with irregular follow-up. HBsAg loss
was found in 2006. However, he had no detectable antibody to
hepatitis B surface antigen (anti-HBs) at that time and had not
received follow-up since then. This time, HCC was diagnosed
due to an abdominal computed tomography (CT) scan disclosing
a solitary mass 8.3 cm in size with early enhancement in the arte-
rial phase and rapid washout in the portal-venous phase at the
right lobe of the liver. Serum biochemistry test results were as
follows: alanine aminotransferase (ALT) 33 IU/L (normal, 0–
40 IU/L), aspartate aminotransferase (AST) 80 IU/L (normal, 5–
45 IU/L), total bilirubin 0.45 mg/dl (normal, 0.2–1.6 mg/dl), and
alpha-fetal protein (AFP) 122,000 ng/ml (normal, <20 ng/ml).
The HBV markers were as follows: HBsAg negative, anti-HBs neg-
ative, and anti-HBc positive (see Fig. 1).
The patient refused resection surgery and underwent TACE
three times from October 2008 to February 2009. However, ele-
vated serum AST (628 IU/L) and ALT (637 IU/L) levels were found
in April 2009. Serum HBsAg reverted back to positive and the
HBV DNA level was 3.84  105 IU/ml measured by polymerase
chain reaction (PCR) (Roche Diagnostics, Basel, Switzerland) with
a limit of detection of 6 IU/ml. Anti-viral therapy with entecavir
was prescribed in a dosage of 0.5 mg orally once a day with the
diagnosis of chronic hepatitis B with acute exacerbation. After
entecavir therapy for two months, serum HBsAg became negative
again with undetectable HBV DNA by PCR. The serum bilirubin
level was not elevated in this period.
According to the recent clinical practice guidelines of the
European Association for the Study of the Liver (EASL), all can-Journal of Hepatology 20didates for chemotherapy should be tested for HBsAg and anti-
HBc before treatment [3]. HBsAg-positive patients should
receive pre-emptive anti-viral therapy during therapy and an
additional 12 months of consolidation therapy after the cessa-
tion of chemotherapy. However, for HBsAg-negative, anti-HBc-
positive patients, pre-emptive anti-viral therapy for HBV is
not routinely suggested. Anti-viral therapy is initiated when
the reactivation of HBV occurs. However, severe fetal reactiva-
tion of HBV has been reported for such patients receiving
potent chemotherapy, even in the case of early application of
anti-viral therapy with lamivudine [1,6]. Hence, pre-emptive
anti-viral therapy, the application of more potent anti-viral
therapy when reactivation occurs, or closer monitoring may
be needed for such patients.
Similarly, for HBsAg-positive patients with HCC undergoing
TACE, HBV reactivation associated with hepatitis ﬂares have been
reported in previous studies [5,7]. HCC patients often also suffer
from impaired liver functional reserve at the time of diagnosis
and treatment. This may cause a more serious and profound
impact if the reactivation of HBV occurs during therapy. In a pre-
vious study, HBV reactivation emerged in 30 of 146 (20.5%)
patients with HCC undergoing TACE [7]. More importantly, three
of them died of hepatic decompensation. Pre-emptive lamivudine
therapy has been demonstrated to reduce the incidence of hepa-
titis due to HBV reactivation [5]. However, long-term lamivudine
therapy causes the selection of drug-resistant HBV mutants,
which may be fatal in patients with impaired liver functional
reserve. Consequently, the application of more potent anti-viral
therapy with higher genetic barriers of resistance, such as enteca-
vir, may improve clinical outcomes.
For patients who are sera HBsAg-negative and anti-HBc-posi-
tive, the incidence and management strategy of HBV reactivation
during TACE for HCC have not been well studied to date. Our cur-
rent case highlights that reactivation of HBV does occur in such
patients. Additionally, HBsAg loss with undetectable serum HBV
DNA was achieved within two months of entecavir therapy. Con-
sequently, in the case of patients with negative serum HBsAg but
positive anti-HBc, it is still mandatory to closely monitor serum
ALT, HBsAg, as well as HBV DNA levels after the application of
TACE, as with those receiving potent chemotherapy. Anti-viral
therapy should be prescribed immediately when the reactivation
of HBV occurs. Entecavir may serve as a suitable therapy for such
patients with advanced hepatic ﬁbrosis and impaired liver func-
tional reserve.
In conclusion, our study demonstrates that the reactivation of
HBV associated with clinically signiﬁcant hepatitis can occur in
HBsAg-negative, but not in anti-HBc-positive patients with HCC10 vol. 52 j 463–465
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Fig. 1. Clinical course of the patient. The serial change of serological marker, serum HBV-DNA, alanine aminotransferase (ALT), and prothrombin time international
normalized ratio (PTINR) during and after TACE are shown.
Letter to the Editorundergoing TACE. Prompt anti-viral therapy with entecavir can
suppress viral replication efﬁciently with the rapid achievement
of virological as well as serological response.Potential conﬂicts of interest
Nothing to report for all authors.
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